- Events
ONCO STARTUP SUMMIT : Le vécu de la startup “Quelle situation et perspective 2024 du marché de l’investissement pour les startups en oncologie”
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
